Top

Published in:

01-08-2014 | IMMUNOLOGY AT THE UNIVERSITY OF IOWA

The CD4 T cell response to respiratory syncytial virus infection

Authors: Allison F. Christiaansen, Cory J. Knudson, Kayla A. Weiss, Steven M. Varga

Published in: Immunologic Research | Issue 1-3/2014

Abstract

Respiratory syncytial virus (RSV) can induce severe lower respiratory tract infections in infants and is the leading cause of bronchiolitis in children worldwide. RSV-induced inflammation is believed to contribute substantially to the severity of disease. T helper (Th)2-, Th9-, and Th17-related cytokines are all observed in infants hospitalized following a severe RSV infection. These cytokines cause an influx of inflammatory cells, resulting in mucus production and reduced lung function. Consistent with the data from RSV-infected infants, CD4 T cell production of Interleukin (IL)-9, IL-13, and IL-17 has all been shown to contribute to RSV-induced disease in a murine model of RSV infection. Conversely, murine studies indicate that the combined actions of regulatory factors such as CD4 regulatory T cells and IL-10 inhibit the inflammatory cytokine response and limit RSV-induced disease. In support of this, IL-10 polymorphisms are associated with susceptibility to severe disease in infants. Insufficient regulation and excess inflammation not only impact disease following primary RSV infection it can also have a major impact following vaccination. Prior immunization with a formalin-inactivated (FI-RSV) vaccine resulted in enhanced disease in infants following a natural RSV infection. A Th2 CD4 T cell response has been implicated to be a major contributor in mediating vaccine-enhanced disease. Thus, future RSV vaccines must induce a balanced CD4 T cell response in order to facilitate viral clearance while inducing proper regulation of the immune response.

Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. The Lancet. 2010;375(9725):1545–55. doi:10.1016/S0140-6736(10)60206-1.CrossRef

Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140(6):543–6.PubMed

Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997–2006. Pediatr Infect Dis J. 2012;31(1):5–9. doi:10.1097/INF.0b013e31822e68e6.CrossRefPubMed

Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol. 2007;20(1):108–19. doi:10.1038/modpathol.3800725.CrossRefPubMed

Kim HW, Leikin SL, Arrobio J, Brandt CD, Chanock RM, Parrott RH. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res. 1976;10(1):75–8. doi:10.1203/00006450-197601000-00015.CrossRefPubMed

Connors M, Collins PL, Firestone CY, Sotnikov AV, Waitze A, Davis AR, et al. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia—RSV recombinants or RSV. Vaccine. 1992;10(7):475–84.CrossRefPubMed

Connors M, Giese NA, Kulkarni AB, Firestone CY, Morse HC 3rd, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol. 1994;68(8):5321–5.PubMedCentralPubMed

Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest. 1991;88(3):1026–33. doi:10.1172/jci115362.PubMedCentralCrossRefPubMed

You D, Marr N, Saravia J, Shrestha B, Lee GI, Turvey SE, et al. IL-4Rα on CD4⁺ T cells plays a pathogenic role in respiratory syncytial virus reinfection in mice infected initially as neonates. J Leukoc Biol. 2013;93(6):933–42. doi:10.1189/jlb.1012498.PubMedCentralCrossRefPubMed

10.

Taylor S, Bryson YJ. Impaired production of gamma-interferon by newborn cells in vitro is due to a functionally immature macrophage. J Immunol. 1985;134(3):1493–7.PubMed

11.

Garofalo RP, Patti J, Hintz KA, Hill V, Ogra PL, Welliver RC. Macrophage inflammatory protein-1α (not T helper type 2 cytokines) is associated with severe forms of respiratory syncytial virus bronchiolitis. J Infect Dis. 2001;184(4):393–9. doi:10.1086/322788.CrossRefPubMed

12.

Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med. 2003;168(6):633–9. doi:10.1164/rccm.200210-1148OC.CrossRefPubMed

13.

Murai H, Terada A, Mizuno M, Asai M, Hirabayashi Y, Shimizu S, et al. IL-10 and RANTES are elevated in nasopharyngeal secretions of children with respiratory syncytial virus infection. Allergol Int. 2007;56(2):157–63. doi:10.2332/allergolint.O-06-454.CrossRefPubMed

14.

RomÁN M, Calhoun WJ, Hinton KL, AvendaÑO LF, Simon V, Escobar AM, et al. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am J Respir Crit Care Med. 1997;156(1):190–5. doi:10.1164/ajrccm.156.1.9611050.CrossRefPubMed

15.

Pinto RA, Arredondo SM, Bono MR, Gaggero AA, Diaz PV. T helper 1/T helper 2 cytokine imbalance in respiratory syncytial virus infection is associated with increased endogenous plasma cortisol. Pediatrics. 2006;117(5):e878–86. doi:10.1542/peds.2005-2119.CrossRefPubMed

16.

Brandenburg AH, Kleinjan A, van het Land B, Moll HA, Timmerman HH, de Swart RL, et al. Type 1-like immune response is found in children with respiratory syncytial virus infection regardless of clinical severity. J Med Virol. 2000;62(2):267–77. doi:10.1002/1096-9071(200010)62:2<267::AID-JMV20>3.0.CO;2-8.CrossRefPubMed

17.

Tabarani CM, Bonville CA, Suryadevara M, Branigan P, Wang D, Huang D, et al. Novel inflammatory markers, clinical risk factors, and virus type associated with severe respiratory syncytial virus infection. Pediatr Infect Dis J. 2013;. doi:10.1097/INF.0b013e3182a14407.PubMedCentralPubMed

18.

Lukacs NW, Moore ML, Rudd BD, Berlin AA, Collins RD, Olson SJ, et al. Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus. Am J Pathol. 2006;169(3):977–86. doi:10.2353/ajpath.2006.051055.PubMedCentralCrossRefPubMed

19.

Stokes KL, Chi MH, Sakamoto K, Newcomb DC, Currier MG, Huckabee MM, et al. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J Virol. 2011;85(12):5782–93. doi:10.1128/jvi.01693-10.PubMedCentralCrossRefPubMed

20.

Tekkanat KK, Maassab HF, Cho DS, Lai JJ, John A, Berlin A, et al. IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent. J Immunol. 2001;166(5):3542–8.CrossRefPubMed

21.

Kaiko GE, Phipps S, Angkasekwinai P, Dong C, Foster PS. NK cell deficiency predisposes to viral-induced Th2-type allergic inflammation via epithelial-derived IL-25. J Immunol. 2010;185(8):4681–90. doi:10.4049/jimmunol.1001758.CrossRefPubMed

22.

Durant LR, Makris S, Voorburg CM, Loebbermann J, Johansson C, Openshaw PJM. Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice. J Virol. 2013;87(20):10946–54. doi:10.1128/JVI.01295-13JVI.01295-13.PubMedCentralCrossRefPubMed

23.

Soroosh P, Doherty TA. Th9 and allergic disease. Immunology. 2009;127(4):450–8. doi:10.1111/j.1365-2567.2009.03114.x.PubMedCentralCrossRefPubMed

24.

Dodd JS, Lum E, Goulding J, Muir R, Van Snick J, Openshaw PJM. IL-9 regulates pathology during primary and memory responses to respiratory syncytial virus infection. J Immunol. 2009;183(11):7006–13. doi:10.4049/jimmunol.0900085.CrossRefPubMed

25.

McNamara PS, Flanagan BF, Baldwin LM, Newland P, Hart CA, Smyth RL. Interleukin 9 production in the lungs of infants with severe respiratory syncytial virus bronchiolitis. The Lancet. 2004;363(9414):1031–7. doi:10.1016/S0140-6736(04)15838-8.CrossRef

26.

Schuurhof A, Bont L, Siezen CL, Hodemaekers H, van Houwelingen HC, Kimman TG, et al. Interleukin-9 polymorphism in infants with respiratory syncytial virus infection: an opposite effect in boys and girls. Pediatr Pulmonol. 2010;45(6):608–13. doi:10.1002/ppul.21229.PubMed

27.

Oboki K, Ohno T, Saito H, Nakae S. Th17 and allergy. Allergol Int. 2008;57(2):121–34. doi:10.2332/allergolint.R-07-160.CrossRefPubMed

28.

Mukherjee S, Lindell DM, Berlin AA, Morris SB, Shanley TP, Hershenson MB, et al. IL-17–induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am J Pathol. 2011;179(1):248–58. doi:10.1016/j.ajpath.2011.03.003.PubMedCentralCrossRefPubMed

29.

Chen Y, Thai P, Zhao Y-H, Ho Y-S, DeSouza MM, Wu R. Stimulation of airway mucin gene expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem. 2003;278(19):17036–43. doi:10.1074/jbc.M210429200.CrossRefPubMed

30.

Fujisawa T, Chang MM-J, Velichko S, Thai P, Hung L-Y, Huang F, et al. NF-κB mediates IL-1β–and IL-17A–induced MUC5B expression in airway epithelial cells. Am J Respir Cell Mol Biol. 2011;45(2):246–52. doi:10.1165/rcmb.2009-0313OC.PubMedCentralCrossRefPubMed

31.

Song C, Luo L, Lei Z, Li B, Liang Z, Liu G, et al. IL-17-producing alveolar macrophages mediate allergic lung inflammation related to asthma. J Immunol. 2008;181(9):6117–24.CrossRefPubMed

32.

Scanlon ST, McKenzie ANJ. Type 2 innate lymphoid cells: new players in asthma and allergy. Curr Opin Immunol. 2012;24(6):707–12. doi:10.1016/j.coi.2012.08.009.CrossRefPubMed

33.

Bradding P, Roberts JA, Britten KM, Montefort S, Djukanovic R, Mueller R, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol. 1994;10(5):471–80. doi:10.1165/ajrcmb.10.5.8179909.CrossRefPubMed

34.

Ying S, Humbert M, Barkans J, Corrigan CJ, Pfister R, Menz G, et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4⁺ and CD8⁺ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol. 1997;158(7):3539–44.PubMed

35.

Fulton RB, Meyerholz DK, Varga SM. Foxp3⁺ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J Immunol. 2010;185(4):2382–92. doi:10.4049/jimmunol.1000423.PubMedCentralCrossRefPubMed

36.

Lee DCP, Harker JAE, Tregoning JS, Atabani SF, Johansson C, Schwarze J, et al. CD25⁺ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection. J Virol. 2010;84(17):8790–8. doi:10.1128/jvi.00796-10.PubMedCentralCrossRefPubMed

37.

Liu J, Ruckwardt TJ, Chen M, Johnson TR, Graham BS. Characterization of respiratory syncytial virus M- and M2-specific CD4 T cells in a murine model. J Virol. 2009;83(10):4934–41. doi:10.1128/jvi.02140-08.PubMedCentralCrossRefPubMed

38.

Loebbermann J, Thornton H, Durant L, Sparwasser T, Webster KE, Sprent J, et al. Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection. Mucosal Immunol. 2012;5(2):161–72. doi:10.1038/mi.2011.62.PubMedCentralCrossRefPubMed

39.

Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011;332(6029):600–3. doi:10.1126/science.1202947.PubMedCentralCrossRefPubMed

40.

Weiss KA, Christiaansen AF, Fulton RB, Meyerholz DK, Varga SM. Multiple CD4⁺ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection. J Immunol. 2011;187(6):3145–54. doi:10.4049/jimmunol.1100764.PubMedCentralCrossRefPubMed

41.

Loebbermann J, Schnoeller C, Thornton H, Durant L, Sweeney NP, Schuijs M, et al. IL-10 regulates viral lung immunopathology during acute respiratory syncytial virus infection in mice. PLoS ONE. 2012;7(2):e32371. doi:10.1371/journal.pone.0032371.PubMedCentralCrossRefPubMed

42.

Sun J, Cardani A, Sharma AK, Laubach VE, Jack RS, Müller W, et al. Autocrine regulation of pulmonary inflammation by effector T-cell derived IL-10 during infection with respiratory syncytial virus. PLoS Pathog. 2011;7(8):e1002173. doi:10.1371/journal.ppat.1002173.PubMedCentralCrossRefPubMed

43.

Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4⁺ T cells. Eur J Immunol. 2007;37(1):129–38. doi:10.1002/eji.200636435.CrossRefPubMed

44.

Ruckwardt TJ, Bonaparte KL, Nason MC, Graham BS. Regulatory T cells promote early influx of CD8⁺ T cells in the lungs of respiratory syncytial virus-infected mice and diminish immunodominance disparities. J Virol. 2009;83(7):3019–28. doi:10.1128/JVI.00036-09.PubMedCentralCrossRefPubMed

45.

Everard ML, Swarbrick A, Wrightham M, McIntyre J, Dunkley C, James PD, et al. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child. 1994;71(5):428–32.PubMedCentralCrossRefPubMed

46.

Bem RA, Bos AP, Bots M, Wolbink AM, van Ham SM, Medema JP, et al. Activation of the granzyme pathway in children with severe respiratory syncytial virus infection. Pediatr Res. 2008;63(6):650–5. doi:10.1203/PDR.0b013e31816fdc32.CrossRefPubMed

47.

McNamara PS, Ritson P, Selby A, Hart CA, Smyth RL. Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis. Arch Dis Child. 2003;88(10):922–6.PubMedCentralCrossRefPubMed

48.

Schuurhof A, Janssen R, de Groot H, Hodemaekers HM, de Klerk A, Kimpen JL, et al. Local interleukin-10 production during respiratory syncytial virus bronchiolitis is associated with post-bronchiolitis wheeze. Respir Res. 2011;12:121. doi:10.1186/1465-9921-12-121.PubMedCentralCrossRefPubMed

49.

Sheeran P, Jafri H, Carubelli C, Saavedra J, Johnson C, Krisher K, et al. Elevated cytokine concentrations in the nasopharyngeal and tracheal secretions of children with respiratory syncytial virus disease. Pediatr Infect Dis J. 1999;18(2):115–22.CrossRefPubMed

50.

Hoebee B, Bont L, Rietveld E, van Oosten M, Hodemaekers HM, Nagelkerke NJ, et al. Influence of promoter variants of interleukin-10, interleukin-9, and tumor necrosis factor-alpha genes on respiratory syncytial virus bronchiolitis. J Infect Dis. 2004;189(2):239–47. doi:10.1086/380908.CrossRefPubMed

51.

Wilson J, Rowlands K, Rockett K, Moore C, Lockhart E, Sharland M, et al. Genetic variation at the IL10 gene locus is associated with severity of respiratory syncytial virus bronchiolitis. J Infect Dis. 2005;191(10):1705–9. doi:10.1086/429636.CrossRefPubMed

52.

Lazarus R, Klimecki WT, Palmer LJ, Kwiatkowski DJ, Silverman EK, Brown A, et al. Single-nucleotide polymorphisms in the interleukin-10 gene: differences in frequencies, linkage disequilibrium patterns, and haplotypes in three United States ethnic groups. Genomics. 2002;80(2):223–8.CrossRefPubMed

53.

Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89(4):422–34.PubMed

54.

Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol. 1969;89(4):435–48.PubMed

55.

Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol. 1969;89(4):405–21.PubMed

56.

Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol. 1969;89(4):449–63.PubMed

57.

Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol. 1986;57(3):721–8.PubMedCentralPubMed

58.

Vaux-Peretz F, Meignier B. Comparison of lung histopathology and bronchoalveolar lavage cytology in mice and cotton rats infected with respiratory syncytial virus. Vaccine. 1990;8(6):543–8.CrossRefPubMed

59.

Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC 3rd, Sotnikov AV, et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4⁺ T cells. J Virol. 1992;66(12):7444–51.PubMedCentralPubMed

60.

Johnson TR, Parker RA, Johnson JE, Graham BS. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol. 2003;170(4):2037–45.CrossRefPubMed

61.

Boukhvalova MS, Prince GA, Soroush L, Harrigan DC, Vogel SN, Blanco JC. The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. Vaccine. 2006;24(23):5027–35. doi:10.1016/j.vaccine.2006.03.064.CrossRefPubMed

62.

Johnson TR, Rao S, Seder RA, Chen M, Graham BS. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine. 2009;27(23):3045–52. doi:10.1016/j.vaccine.2009.03.026.PubMedCentralCrossRefPubMed

63.

Loebbermann J, Durant L, Thornton H, Johansson C, Openshaw PJ. Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells. Proc Natl Acad Sci USA. 2013;110(8):2987–92. doi:10.1073/pnas.12175801101217580110.PubMedCentralCrossRefPubMed

64.

Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol. 1992;4(4):493–500.CrossRefPubMed

65.

Openshaw PJ, Anderson K, Wertz GW, Askonas BA. The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection. J Virol. 1990;64(4):1683–9.PubMedCentralPubMed

66.

Varga SM, Wissinger EL, Braciale TJ. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4⁺ T cell responses. J Immunol. 2000;165(11):6487–95.CrossRefPubMed

67.

Varga SM, Wang X, Welsh RM, Braciale TJ. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4⁺ T cells. Immunity. 2001;15(4):637–46.CrossRefPubMed

68.

Castilow EM, Legge KL, Varga SM. Cutting edge: eosinophils do not contribute to respiratory syncytial virus vaccine-enhanced disease. J Immunol. 2008;181(10):6692–6. doi:10.4049/jimmunol.181.10.6692.PubMedCentralCrossRefPubMed

69.

Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009;15(1):34–41. doi:10.1038/nm.1894.PubMedCentralCrossRefPubMed

70.

Olson MR, Varga SM. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J Immunol. 2007;179(8):5415–24. doi:10.4049/jimmunol.179.8.5415.CrossRefPubMed

71.

Olson MR, Hartwig SM, Varga SM. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J Immunol. 2008;181(11):7958–68. doi:10.4049/jimmunol.181.11.7958.PubMedCentralCrossRefPubMed

Title: The CD4 T cell response to respiratory syncytial virus infection
Authors: Allison F. Christiaansen
Cory J. Knudson
Kayla A. Weiss
Steven M. Varga
Publication date: 01-08-2014
Publisher: Springer US
Published in: Immunologic Research / Issue 1-3/2014
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-014-8540-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The CD4 T cell response to respiratory syncytial virus infection

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-3/2014

Toll-like receptors and B cells: functions and mechanisms

Effects of obesity on immune responses to renal tumors

Chronic infection by Leishmania amazonensis mediated through MAPK ERK mechanisms

Staphylococcal toxic shock syndrome: superantigen-mediated enhancement of endotoxin shock and adaptive immune suppression

NLR proteins and parasitic disease

Correlates of protective immunity following whole sporozoite vaccination against malaria